Background: Few data is available in low-burden TB-HIV countries on TB treatment outcomes. We evaluated TB patients (pts) characteristics by HIV status and compared treatment outcomes in relation to HIV status, CD4 count and antiretroviral therapy (ART). Methods: We performed a retrospective analysis of 447 adult TB pts who registered and initiated treatment in our center from 2014 to 2015. Results: Pts were categorized as HIV-negative (n = 399, 89.3%), HIV-positive on ART (n = 42, 9.4%) and HIV-positive not on ART (n = 6, 1.3%). The proportion of pts with extended TB therapy was higher among HIV-positive pts (p = 0.03). Increased age was associated with higher death rates regarding treatment success (OR 1.08; 95% CI 1.01 -1.17, p = 0.03). Statistically significant higher mortality was found among HIV-positive pts on ART (OR 9.93; 95% CI 1.36 -72.37, p = 0.03) and HIV-positive pts not on ART (OR 397.00; 95% CI 44.27 to 3559.91, p ≤ 0.0001) compared to HIV-negative pts. When multivariate analyses were restricted to HIV-positive pts, being not on ART was associated with higher mortality (OR 40.0; 95% CI 4.37 -365.78, p = 0.001). Conclusions: There was significant difference in death rates between HIV-positive and HIV-negative TB pts. HIV-positive pts not on ART had a significantly higher mortality.
edged as one of the leading causes of death among human immunodeficiency virus (HIV)-infected patients [2] . In 2016, the majority of the estimated TB cases occurred in Asia (45%) and the World Health Organization (WHO) African Region (25%). Less significant number of TB cases happened in the Eastern Mediterranean Region (7%), European Region (3%) and Americas Region (3%) [1] .
In recent years, there has been a decline in the incidence of TB in Portugal, reaching the 20/100,000 population threshold in 2014. Additionally, there was also a decrease in the reported number of new HIV infection cases. The decline in TB incidence stands at 18/100,000 inhabitants in 2016 [3] . Compared to HIV-negative patients, HIV-positive TB patients can be more challenging to TB centers. TB-HIV co-infection poses more difficulties in the management of both diseases that may result in adherence decrease due to immune reconstitution inflammatory syndrome, high tablet problem with drug interactions and challenging toxicity profiles [4] . To reach the ideal approach, patients need standardized anti-tuberculosis treatment, while HIV-positive TB patients requisite additional antiretroviral treatment (ART). Furthermore, HIV-positive TB patients are more likely to be infectious for longer and to have diagnostic postponements due to the disease atypical presentation, resulting in poorer TB treatment outcomes [5] [6] . It is recognised that initiation of ART earlier in HIV infection improves outcomes, and international guidelines have been updated to reflect this. Data suggest that early TB treatment in HIV-infected people reduces morbidity and mortality, and appropriate treatment regimens are often successful
HIV infection may severely influence TB treatment outcomes. Several studies with mixed results from high-burden TB countries have considered the impact of HIV infection on TB treatment outcomes. However, few data is available in low-burden TB-HIV countries. In high-burden TB/HIV settings, some studies have revealed worse TB treatment outcomes in HIV-positive TB patients when paralleled to HIV-negative TB patients [7] [8] [9] [10] [11] [12] , while other data established that TB treatment outcomes did not diverge between the two groups [13] [14] . Since the initiation of ART, it has been progressively recognized that HIV-positive TB patients are a heterogeneous group, and TB mortality during TB treatment will diverge between HIV-positive TB patients on ART and those not on ART. To date, few data are available in low-burden TB-HIV countries on TB mortality in HIV-positive TB patients on ART, and HIV-positive TB patients not on ART comparative to HIV-negative TB patients. In order to guarantee resources availability for TB and HIV management, it is imperative that countries monitor for co-infection in order to diagnose, treat and prevent TB-HIV co-infection, thus decreasing TB burden and increasing the quality of life of people living with HIV.
The aim of the study, therefore, was to evaluate TB patients' characteristics by HIV status and compare TB treatment outcomes (mortality and success) in relation to HIV status, CD4 count and ART in HIV-positive patients on ART, and 
Materials and Methods

Population and Design
We performed a retrospective cohort study conducted at the Pulmonology Diagnosis Center Dr. Ribeiro Sanches that provides TB diagnosis, treatment and monitoring to the regional area of Lisbon-the capital city of Portugal. This center is one of the major public health centers in Portugal that provides service for people with TB. TB services are fully integrated in this center: medical and nursery consultations with periodic monitoring and evaluation, the adherence support and TB treatment dispensed by trained TB nurses.
Inclusion and Exclusion Criteria
We included all new adult TB patients (aged ≥ 18 years) who registered and initiated TB treatment in our center between 1 January 2014 and 31 December 2015. We excluded 101 patients: 50 patients for whom treatment outcomes were inconclusive (unknown or transferred out), 44 patients who failed treatment and 7 patients who had not concluded treatment for unsupported diagnosis ( Figure  1 ). All patients had known HIV status, according to the need to screen at least 80% of all TB patients for HIV as proposed by the WHO recommendations.
Data Collection
Data from the Center registry database were collected and completed by reviewing patient clinical records and paper-based TB registers. Variables for all patients 
Outcome Measures and Definitions
We used internationally recommended definitions for TB treatment outcomes, namely cured, treatment completed and death [15] . Cure was defined as the occurrence of a negative sputum smear at the last month of treatment and at least on one additional occasion during the TB treatment. Treatment completion was defined as completed TB treatment, but for whom smear examination results
were not complete to categorize the patient as cured; or based on clinical, radiological and complementary examination criteria in patients that did not produce sputum for a smear examination. Treatment success referred to patients "cured"
and with "treatment completed". Death was considered all-cause mortality after TB diagnosis and previously to the end of TB treatment.
Anti-Tuberculosis and Antiretroviral Treatment
Standardized anti-tuberculosis treatment for new adult TB cases was a four-drug regimen of isoniazid, rifampicin, pyrazinamide and ethambutol during the two initial months ("intensive phase") followed by isoniazid and rifampicin during at least four months ("continuation phase") [16] . Antiretroviral therapy was accessible to HIV-positive patients not on ART according to the European and Portuguese ART guidelines [17] [18]. 
Statistical Analysis
Results
A total of 548 new TB patients aged ≥ 18 years old were registered between January 2014 and December 2015 (Figure 1) . The new TB patients (n = 101) for whom TB treatment completion status was inconclusive (unknown or transferred out) or who failed TB treatment were exclude (Figure 1 ). The patient cohort was then formed by 447 patients. HIV status in this sample was classified as HIV-negative, in 399 patients (89.3%) and HIV-positive, in 48 patients (10.7%). HIV-positive on ART, in 42 patients (9.4%) and HIV-positive not on ART, in 6 patients (1.3%) ( Table 1 ). The proportion of male patients was higher in all groups (p = 0.003; Table 1 ). The proportion of patients with smear-positive TB was higher among HIV-positive not on ART (p = 0.005). No significant differences were established in age, place of residence, education or smoking behavior for each category. The death rate was higher in HIV-positive not on ART compared to the other groups (p < 0.001) ( Table 1) . Among HIV-positive TB patients (n = 48), the median CD4 count was higher in patients HIV-positive on ART than HIV-positive not on ART (Table 1) . The proportion of patients who had extended TB therapy was higher among HIV-positive patients (p = 0.03). Only 6 patients (12.5%) of HIV-positive TB patients eligible for ART did not initiate ART during their TB treatment (Figure 1 ).
In Table 2 are presented the results of multinomial logistic regression analysis 
Discussion
This study evaluated the impact of HIV, CD4 cell count and ART status on TB treatment outcomes in 447 new TB patients. Death rates were considerably higher in HIV-positive patients on ART and HIV-positive patients not on ART than in HIV-negative patients. Our study has some conflicting results when compared to some data from high-burden TB/HIV countries. A study among patients accessing an integrated TB and ART service in South Africa showed no differences in death rates between HIV-positive TB patients on ART and HIV-negative TB patients, but similar results to ours when comparing HIV-positive patients not on ART to HIV-negative patients concerning death rates [19] . This discrepancy is probable connected to the dissimilar prevalence of other diseases between different populations, differences in institutional tasks and patient's selection criteria. ART during a TB treatment event significantly improve mortality rates for the HIV-positive TB patients. Our data evidently designate that ART uptake should be upgraded with an improved follow-up of patients with HIV-associated TB. Our study result that throughout a TB treatment ART uptake was significantly associated with improved mortality rates, is comparable to studies with patients using acombined TB and ART service in high-burden countries [11] [12] [13] . In our study, we did not find an impact of CD4 cell counts on mortality. Several studies from Africa [20] In this study, type of TB was not significantly associated with TB treatment outcomes in new TB patients and in the subgroup of HIV-positive TB patients.
Previous studies from high-burden countries, revealed that comparing to smear-positive TB patients, the odds of mortality were 4 times higher for smear-negative patients and 2.7 times higher for extrapulmonary patients [24] .
Additionally, current literature also showed a higher prevalence of HIV in patients with smear-negative pulmonary TB and extrapulmonary TB. TB diagnosis challenges and the resulting postponement in treatment initiation may result in higher mortality among smear-negative pulmonary TB and extrapulmonary TB patients [25] . 
Conclusion
In conclusion, this study showed that there was significant difference in death rates between HIV-positive and HIV-negative TB patients. HIV-positive patients not on ART had a significantly higher mortality. These findings strain the need for an intervention aimed at preventing TB-HIV co-infection and improving ART uptake. Further research is needed into the burden and associated risk factors of co-infection in Europe, to help plan effective control measures. Increased HIV testing of TB patients and targeted and informed strategies for control and prevention could help curb the co-infection epidemic. Journal of Tuberculosis Research ter Dr. Ribeiro Sanches.
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